81 related articles for article (PubMed ID: 3542407)
1. Passive protection of NMRI mice with commercial, intravenously applicable human immunoglobulin IgG preparations against Serratia marcescens.
Traub WH
Chemotherapy; 1986; 32(6):530-6. PubMed ID: 3542407
[TBL] [Abstract][Full Text] [Related]
2. Passive protection of NMRI mice against Serratia marcescens: comparative efficacy of commercial human IgG immunoglobulin preparations and rabbit anti-O, -H, -K, -life cell and -protease immune sera.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Jul; 254(4):480-8. PubMed ID: 6202079
[TBL] [Abstract][Full Text] [Related]
3. Failure of a commercial, intravenously applicable IgG F (ab)2 preparation (Gamma-Venin) to enhance human serum bactericidal activity against Serratia marcescens.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 249(4):504-11. PubMed ID: 6171949
[TBL] [Abstract][Full Text] [Related]
4. Human serum bactericidal activity against Serratia marcescens: failure of human, "natural," specific anti-O IgG antibodies to enhance serum bactericidal activity.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 250(1-2):84-91. PubMed ID: 7032154
[TBL] [Abstract][Full Text] [Related]
5. Phagocytosis of Serratia marcescens by leukocytes of fresh defibrinated human blood: failure of "natural" human specific anti-O IgG antibodies to enhance phagocytosis.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981; 250(1-2):92-103. PubMed ID: 7032156
[TBL] [Abstract][Full Text] [Related]
6. Active immunization of NMRI mice against Serratia marcescens. II. K-antigen extracts.
Traub WH; Spohr M; Bauer D
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Dec; 267(2):228-46. PubMed ID: 3328927
[TBL] [Abstract][Full Text] [Related]
7. Failure of the commercial human IgG immunoglobulin preparation Polyglobin to enhance combined phagocytic and serum bactericidal activity of normal blood against Serratia marcescens.
Traub WH
Chemotherapy; 1983; 29(1):43-7. PubMed ID: 6339179
[TBL] [Abstract][Full Text] [Related]
8. Specific and Nonspecific immunity to Serratia marcescens infection.
Simberkoff MS; Moldover NH; Rahal JJ
J Infect Dis; 1976 Oct; 134(4):348-53. PubMed ID: 789788
[TBL] [Abstract][Full Text] [Related]
9. Towards serodiagnosis of Serratia marcescens infections: examination of sera from noninfected patients and from experimentally infected rabbits for anti-H and anti-O antibodies; S. marcescens O-antigen cross-reactions with those of other enterobacteriaceae.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):490-6. PubMed ID: 7036590
[TBL] [Abstract][Full Text] [Related]
10. Virulence of nosocomial isolates of Serratia marcescens for NMRI mice: correlation with O-antigens O6 and O14.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jul; 252(3):360-9. PubMed ID: 6182709
[TBL] [Abstract][Full Text] [Related]
11. Active immunization of NMRI mice against Serratia marcescens.
Traub WH; Spohr M; Bauer D
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 May; 259(3):410-25. PubMed ID: 3901614
[TBL] [Abstract][Full Text] [Related]
12. Active immunization of NMRI mice against Serratia marcescens. I. Phenol-water lipopolysaccharide fractions and purified metalloproteases.
Traub WH; Spohr M; Bauer D
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jun; 265(1-2):182-96. PubMed ID: 3314256
[TBL] [Abstract][Full Text] [Related]
13. Serotyping of Serratia marcescens: simplified tube O-agglutination test and comparison with other serological procedures.
Traub WH; Fukushima PI
Zentralbl Bakteriol Orig A; 1979 Sep; 244(4):474-93. PubMed ID: 396741
[TBL] [Abstract][Full Text] [Related]
14. Opsonization requirements of Serratia marcescens.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Nov; 253(2):204-24. PubMed ID: 6187137
[TBL] [Abstract][Full Text] [Related]
15. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.
Kreger AS; Lyerly DM; Hazlett LD; Berk RS
Invest Ophthalmol Vis Sci; 1986 Jun; 27(6):932-9. PubMed ID: 3519522
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of gram-negative and gram-positive infections using 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection using intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
Collins MS; Hector RF; Roby RE; Edwards AA; Ladehoff DK; Dorsey JH
Infection; 1987; 15(1):60-8. PubMed ID: 3570485
[TBL] [Abstract][Full Text] [Related]
17. Functional role of antibody against "core" glycolipid of Enterobacteriaceae.
Young LS; Stevens P; Ingram J
J Clin Invest; 1975 Oct; 56(4):850-61. PubMed ID: 1099119
[TBL] [Abstract][Full Text] [Related]
18. Effects of vaccination against systemic Serratia infection.
Kumagai Y; Okada K; Ishimaru T; Sawae Y; Kuroiwa A; Nomoto K
J Clin Lab Immunol; 1989 Jul; 29(3):125-32. PubMed ID: 2699333
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of Serratia marcescens to human serum: antagonism of serum bactericidal activity by IgG immunoglobulins of homologous rabbit anti-O sera.
Traub WH
Zentralbl Bakteriol A; 1980 Feb; 246(1):26-49. PubMed ID: 6158811
[TBL] [Abstract][Full Text] [Related]
20. Immunobiology of Clostridium perfringens type A: passive protection of NMRI mice. Western blot analysis of immunoreactive polypeptides.
Traub WH; Bauer D; Wolf U
Chemotherapy; 1991; 37(5):318-26. PubMed ID: 1804593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
